
Newell Brands eyes 40% cash flow jump in 2026 despite tariff headwinds
Newell Brands (NASDAQ:NWL) shares stabilized on Friday after the consumer goods giant signaled a turning point in its multi-year turnaround, projecting a massive surge in cash flow for 2026 even as aggressive new tariffs continue to eat into its bottom line.
The Atlanta-based maker of Sharpie pens and Rubbermaid containers reported fourth-quarter net sales of $1.9 billion, a 2.7% decline that mirrored the broader cooling in discretionary consumer spending.
However, the company’s internal "Productivity Plan"—which included cutting 10% of its professional workforce and shuttering underperforming Yankee Candle stores—is beginning to bear fruit.
Normalized operating margins expanded to 8.7%, up from 7.1% a year ago, as Newell successfully offset volume declines with better overhead absorption and high-margin product innovation.
The real story for investors, however, lies in the 2026 outlook.
CEO Chris Peterson projected that operating cash flow will reach between $350 million and $400 million this year—a midpoint increase of more than 40% compared to 2025.
This surge is expected despite an additional $0.07 per share hit from tariffs and a higher effective tax rate.
Newell is betting that its "How to Win" flywheel—which focuses on Gen Z-targeted marketing for brands like Sharpie and expanding its distribution footprint for the first time in nearly a decade—will finally return the company to flat-to-positive sales growth by the end of the year.
"We exited 2025 a stronger and more resilient company," Peterson told analysts on Friday.
While the company reported a GAAP net loss of $315 million for the quarter—largely due to non-cash restructuring charges—normalized earnings of $0.18 per share beat Wall Street expectations.
More from United States
Oil prices extend gains as Middle East tensions rise
Magna posts higher Q3 earnings despite 4% sales decline
BP Q3 profit jumps to $8.46 billion as debt falls
Sanofi Q3 sales rise 16.2% to €14.44 billion
AstraZeneca revenue advances 7% in Q3 to $16.21 billion
First Northern profit climbs 11.1% to $16.8 million